Table 1.
Oral midazolam calculated pharmacokinetic parameters in preterm infants.
| Midazolam | 1-OH-midazolam | |
|---|---|---|
| AUC(0,t) (ng ml−1 h) | 613 (90–2286) | 68.9 (<0.01–272.6) |
| AUC(0,∞) (ng ml−1 h) | 642 (108–2465) | 71.8 (1.6–305.0)# |
| t½ (h) | 7.6 (1.2–15.1) | NA |
| Vss/F (l kg−1) | 1.4 (0.3–12.1) | NA |
| CL/F (l kg−1 h−1) | 0.16 (0.04–0.93) | NA |
| MRT (h) | 12.0 (3.7–22.7) | NA |
| Cmax (ng ml−1) | 64.4 (15.2–204.0) | 10.3 (<0.01–22.1) |
| tmax (h) | 2.0 (0.5–12.0) | 4.0 (0.5–24.0) |
| AUC ratio | 0.03 (<0.01–0.96) | |
| F (%) | 0.49 (0.12–1.0) |
Data are expressed as: median (range)
#
data of four patients.
Cmax = maximal concentration of drug in plasma, tmax = time to reach Cmax, AUC(0,t) = area under the concentration-time curve from time zero to the last sampling time point, AUC(0,∞) = area under the concentration-time curve from time zero to infinity, t½ = elimination half-life, CL/F = total apparent clearance and Vss/F = apparent volume of distribution at steady state, MRT = mean resident time, AUC ratio = 1-OH-midazolam AUC(0,t)/midazolam AUC(0,t), F = oral bioavailability, NA = not available.